WuXi Biologics to Acquire Pfizer China’s Biologics Manufacturing Facilities
The transaction is set to close during the first half of 2021 and is expected to enhance drug substance and drug product capabilities for WuXi.
WuXi Biologics announced on March 17, 2021 that it has entered into an equity agreement with Pfizer China to acquire its biologics manufacturing facilities and labor force in Hangzhou, China.
The 50,000-m2 facilities feature drug substance (DS) capacities, which include 2 x 2000-L single-use bioreactors expandable to 4 x 2000-L (MFG20) and drug product (DP) capacities of vial filling (DP9) and pre-filled syringe (DP10), WuXi said in a company press release. The transaction is set to close during the first half of 2021 and is expected to enhance DS and DP capabilities for WuXi.
“We are pleased to work with Pfizer and add the new Hangzhou biologics manufacturing facilities to our global network to address the surging manufacturing demands for late-stage and commercial projects due to the success of our Win-the-Molecule strategy,” said Chris Chen, CEO of WuXi Biologics, in the press release. “Globally DS and especially DP capacities are in urgent need now. The acquisition will allow us to better enable our global partners to develop and manufacture premier-quality biologics to benefit patients around the world.”
Source: WuXi Biologics
